Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Biotech Milestones and Database Updates for July 12, 2010

|Includes: ENDP, EyePoint Pharmaceuticals, Inc. (EYPT), INFI, OPTR, RMTI

Below is a sample morning note to clients, which includes new catalysts/milestones added to our database, as well as companies and products that have new data.

Dear Sample Client,

Here are the latest updates at


FCSC: On track to submit data from Azficel-T histology study to FDA in 4Q10 (not disclosed whether data will be made publicly available).

NEOP: Lymphoseek NDA filing expected late summer 2010, data expected 1Q11
from NEO3-09 study.

PSDV: Submitted Iluvien MAA July 8th, expected acceptance August 2010.



RESEARCH IDEAS- BPAX, AVII, CORT, EXAS, ALXA (ask about our rates)

Andrew Nava LLC provides equity research services for both institutional and retail healthcare investors. We focus on fundamental research of small- to mid-cap healthcare companies with the potential for significant market cap appreciation in the next 6-12 months. Our investment theses are based on event-driven catalysts and value-driven growth.

Our research is powered by our database. Information is derived exclusively from public sources and is useful for tracking clinical trial data and upcoming company milestones. As of June 2010, the database covers over 290 publicly-traded biotechnology and pharmaceutical companies, more than 1000 profiles of approved and development-stage drugs, devices and diagnostics, and 17 different catalyst types.

For more information, please visit

Disclosure: No positions